share_log

Tracon Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ikarian Capital, LLC(5.9%),Neil Shahrestani(5.9%)

Tracon Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Ikarian Capital, LLC(5.9%),Neil Shahrestani(5.9%)

Tracon Pharmaceuticals | SC 13G/A：超過5%持股股東披露文件(修正)-Ikarian Capital, LLC(5.9%),Neil Shahrestani(5.9%)
美股SEC公告 ·  04/05 16:16

Moomoo AI 已提取核心訊息

On March 31, 2024, Ikarian Capital, LLC, along with Neil Shahrestani, filed an amended Schedule 13G with the U.S. Securities and Exchange Commission, indicating a shared voting and dispositive power over 2,670,930 shares of Tracon Pharmaceuticals, Inc. This represents 5.9% of the company's common stock, based on the number of shares outstanding as of March 1, 2024. Ikarian Capital, a Delaware-based investment adviser, manages these shares through the Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts. The filing clarifies that neither Ikarian Capital nor Mr. Shahrestani claim beneficial ownership of the reported shares for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, nor do they admit to acting as a group for the purpose of acquiring, holding, or disposing of securities of the issuer.
On March 31, 2024, Ikarian Capital, LLC, along with Neil Shahrestani, filed an amended Schedule 13G with the U.S. Securities and Exchange Commission, indicating a shared voting and dispositive power over 2,670,930 shares of Tracon Pharmaceuticals, Inc. This represents 5.9% of the company's common stock, based on the number of shares outstanding as of March 1, 2024. Ikarian Capital, a Delaware-based investment adviser, manages these shares through the Ikarian Healthcare Master Fund, L.P., and certain separately managed accounts. The filing clarifies that neither Ikarian Capital nor Mr. Shahrestani claim beneficial ownership of the reported shares for the purpose of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, nor do they admit to acting as a group for the purpose of acquiring, holding, or disposing of securities of the issuer.
2024年3月31日，伊卡里安資本有限責任公司與尼爾·沙雷斯塔尼一起向美國證券交易委員會提交了經修訂的附表13G，表示對Tracon Pharmicals, Inc.的2670,930股股票擁有共同的投票權和處置權。根據截至2024年3月1日的已發行股票數量，這佔該公司普通股的5.9％。總部位於特拉華州的投資顧問伊卡里安資本通過伊卡里安醫療主基金有限責任公司和某些單獨管理的賬戶管理這些股票。該文件澄清說，爲了1934年《證券交易法》第13（d）或13（g）條的目的，Ikarian Capital和Shahrestani先生均未聲稱擁有申報股票的受益所有權，他們也不承認以集團形式收購、持有或處置發行人的證券。
2024年3月31日，伊卡里安資本有限責任公司與尼爾·沙雷斯塔尼一起向美國證券交易委員會提交了經修訂的附表13G，表示對Tracon Pharmicals, Inc.的2670,930股股票擁有共同的投票權和處置權。根據截至2024年3月1日的已發行股票數量，這佔該公司普通股的5.9％。總部位於特拉華州的投資顧問伊卡里安資本通過伊卡里安醫療主基金有限責任公司和某些單獨管理的賬戶管理這些股票。該文件澄清說，爲了1934年《證券交易法》第13（d）或13（g）條的目的，Ikarian Capital和Shahrestani先生均未聲稱擁有申報股票的受益所有權，他們也不承認以集團形式收購、持有或處置發行人的證券。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間